Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis on Fiserv Stock and Intuitive surgical

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
27 Sept 2025, 20:18 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an analysis on Fiserv Stock and Intuitive surgical
Source overview

AI-generated source summary

The current market analysis focuses on two stocks: FISV and ISRG. FISV is currently trading at $129.56, down 41.56% year-to-date and showing weakness. While its valuation metrics like P/E ratio and price to free cash flow are low (11.8x and 16.6x respectively), the significant debt load and declining EPS growth might be concerns. The stock has a bearish trend, but a potential bullish reversal is noted if it can break past $150. ISRG, trading at $441.12, has also seen a downturn, down 15.82% year-to-date. Despite a strong long-term growth trend and substantial revenue from recurring services, its recent EPS growth has slowed. The company's extensive installed base of Da Vinci robots and a strong recurring revenue model suggest resilience, but competition from Chinese manufacturers offering cheaper alternatives at 50% lower costs is a factor. A target of $470 is set for ISRG, with a failure bound at $438.50.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail